Copertina

Development and clinical potential of 18F-PSiMA for prostate cancer PET imaging

Prostate-specific membrane antigen (PSMA) is a key target for diagnosing prostate cancer through positron emission tomography (PET). While 68Ga-labeled PSMA compounds are widely used, 18F-labeled PSMA inhibitors have gained traction for clinical tumor imaging. We previously investigated PSMA-targeti...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Gower-Fry, Lexi (Autore) , Bailey, Justin J. (Autore) , Wuest, Melinda (Autore) , Pike, Susan (Autore) , Kostikov, Alexey (Autore) , Dorian, Andreas (Autore) , Wängler, Carmen (Autore) , Wuest, Frank (Autore) , Schirrmacher, Ralf (Autore)
Natura: Article (Journal)
Lingua:inglese
Pubblicazione: 09 May 2025
In: RSC medicinal chemistry
Year: 2025, Volume: 16, Fascicolo: 8, Pages: 3633-3644
ISSN:2632-8682
DOI:10.1039/D5MD00275C
Accesso online:Verlag, kostenfrei, Volltext: https://doi.org/10.1039/D5MD00275C
Verlag, kostenfrei, Volltext: https://pubs.rsc.org/en/content/articlelanding/2025/md/d5md00275c
Testo
Note sull'autore:Lexi Gower-Fry, Justin J. Bailey, Melinda Wuest, Susan Pike, Alexey Kostikov, Andreas Dorian, Carmen Wängler, Frank Wuest and Ralf Schirrmacher
Descrizione
Riassunto:Prostate-specific membrane antigen (PSMA) is a key target for diagnosing prostate cancer through positron emission tomography (PET). While 68Ga-labeled PSMA compounds are widely used, 18F-labeled PSMA inhibitors have gained traction for clinical tumor imaging. We previously investigated PSMA-targeting compounds based on the Lys-urea-Glu motif, incorporating a silicon fluoride-acceptor (SiFA) and chemical auxiliaries to enhance in vivo biodistribution. This led to the development of 18F-PSiMA, a SiFA-based radiotracer with an optimized linker exhibiting favorable PSMA potency (IC50 = 154 ± 47 nM in LNCaP cells). 18F-PSiMA radiosynthesis with low to high concentrations of 18F and precursor achieved molar activities (Am) of 10.9-82.5 GBq μmol−1 and showed a 24-38% increase in tumor uptake in LNCaP tumors (SUV60min 1.56 ± 0.18; 7.23 ± 0.75% ID per g at lower Am and SUV60min 1.90 ± 0.29; 9.62 ± 1.29% ID per g at higher Am) compared to our previous lead, 18F-SiFA-Asp2-PEG3-PSMA. PSMA specificity was confirmed by a 20 ± 10% reduction in SUV60min upon co-injection with DCFPyl. These promising in vitro and in vivo results support further clinical translation of 18F-PSiMA for prostate cancer PET imaging.
Descrizione del documento:Zuerst veröffentlicht: 09. Mai 2025
Gesehen am 17.09.2025
Im Titel ist die Zahl "18" hochgestellt
Descrizione fisica:Online Resource
ISSN:2632-8682
DOI:10.1039/D5MD00275C

Documenti analoghi